Eli Lilly has unveiled a significant package to help nurture early-stage biotechs in the UK and work with the National Health Service on new models of care for obesity, but CEO David Ricks has warned that Brexit means the country needs to be even more responsive to business than its European neighbors to attract investment.
Key Takeaways
Lilly is putting in £279m in new investment into the UK but wants the government to be more business-friendly
Some of the cash will go into the creation of the first Lilly Gateway Labs biotech hub outside the US
There are
Ricks, who was in London for Prime Minister Keir Starmer’s International Investment Summit, pointed out that the UK had become a less attractive place to do business since leaving the European Union
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?